HCW Biologics (HCWB) Non-Current Debt (2022 - 2025)

HCW Biologics (HCWB) has 4 years of Non-Current Debt data on file, last reported at $367151.0 in Q2 2025.

• Quarterly Non-Current Debt fell 96.29% year-over-year to $367151.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $367151.0 (down 96.29% YoY) and the FY2024 annual result came in at $7.4 million, up 17.03% from the prior year.
• Non-Current Debt declined to $367151.0 in Q2 2025, from $7.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.9 million in Q2 2024 to a low of $367151.0 in Q2 2025.
• A 4-year average of $6.5 million and a median of $6.4 million in 2022 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt soared 54.7% — and 2025, when it tumbled 96.29%.
• Tracing HCWB's Non-Current Debt over 4 years: stood at $6.4 million in 2022, then dropped by 1.65% to $6.3 million in 2023, then increased by 17.03% to $7.4 million in 2024, then tumbled by 95.02% to $367151.0 in 2025.
• The last three Non-Current Debt figures came in at $367151.0 (Q2 2025), $7.7 million (Q1 2025), and $7.4 million (Q4 2024), per Business Quant data.